- Verdemed, a Brazilian pharmaceutical company, has recently solidified its authority in the growing cannabis-based medication market with multiple approvals from Anvisa.
- Verdemed presents a range of products, including a solution similar to Jazz Pharmaceuticals' Epidiolex, which contributes to the rising demand for cannabis-based medicinal alternatives in Brazil.
In recent years, the medicinal cannabis industry has seen substantial growth globally. Leading this rapidly growing movement in Brazil is Verdemed, a local pharmaceutical company that has found immense success with its cannabis-based medications. It's notable success, marked by five approvals from National Health Surveillance Agency (Anvisa) in July, has put the company at the forefront of this expanding drug market.
One of Verdemed's offerings that stands out among its range of products is a therapeutic solution which mimics Jazz Pharmaceuticals' Epidiolex. This drug, already having been registered by the FDA, was previously unavailable in Brazil. The introduction of such a critically recognized product into the pharmaceutical market through Verdemed is a significant accomplishment and marks a groundbreaking moment for cannabis-based medicinal treatments in Brazil.
Comments